JP2005511724A - 鼻炎を処置するためのh1アンタゴニストおよび安全なステロイドの使用 - Google Patents
鼻炎を処置するためのh1アンタゴニストおよび安全なステロイドの使用 Download PDFInfo
- Publication number
- JP2005511724A JP2005511724A JP2003550819A JP2003550819A JP2005511724A JP 2005511724 A JP2005511724 A JP 2005511724A JP 2003550819 A JP2003550819 A JP 2003550819A JP 2003550819 A JP2003550819 A JP 2003550819A JP 2005511724 A JP2005511724 A JP 2005511724A
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- composition
- composition comprises
- safe
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003431 steroids Chemical class 0.000 title claims abstract description 22
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 11
- 239000005557 antagonist Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000043 antiallergic agent Substances 0.000 claims abstract description 13
- 239000000938 histamine H1 antagonist Substances 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 229960000325 emedastine Drugs 0.000 claims abstract description 6
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical group N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004114 olopatadine Drugs 0.000 claims abstract description 6
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims abstract description 6
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960001271 desloratadine Drugs 0.000 claims abstract description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims abstract description 3
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims abstract description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960004574 azelastine Drugs 0.000 claims abstract description 3
- 229960003449 epinastine Drugs 0.000 claims abstract description 3
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 229960004958 ketotifen Drugs 0.000 claims abstract description 3
- 229960001120 levocabastine Drugs 0.000 claims abstract description 3
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims abstract description 3
- 229960003088 loratadine Drugs 0.000 claims abstract description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001487 rimexolone Drugs 0.000 claims description 7
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims description 7
- 229960001798 loteprednol Drugs 0.000 claims description 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical class C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Abstract
Description
アレルギー性鼻炎は、経口抗ヒスタミン剤および/または経口ステロイドのレジメンを用いて歴史的に処置されている。全身処置には、代表的には、必要な処置部位に到達するために有効な濃度を提供するために投与されるべき、より高濃度の薬物化合物が必要とされる。抗ヒスタミン化合物は、それ自体を嗜眠状態で表す中枢神経系(CNS)活性を有することが公知である。抗ヒスタミン化合物はまた、粘膜の乾燥においてそれ自体を示す、抗コリン作用性活性を有し得る。ステロイド療法はまた、経口投与されようとまたは鼻内投与されようと、顕著な全身副作用(副腎機能不全、心血管不順、および免疫抑制を包含する)を生じ得る。成長遅延が、アレルギー性の小児患者における特に重要な問題である。
本発明は、鼻炎を処置するための、H1アンタゴニスト/抗アレルギー剤と安全なステロイドとの組み合わせの鼻内組成物に関する。哺乳動物における上記組成物の使用方法もまた、企図される。
本発明は、アレルギー性鼻炎に関係するくしゃみおよび鼻漏を処置するためのH1アンタゴニスト/抗アレルギー剤の組成物を包含する。この組成物はまた、安全なステロイドも含む。本明細書中で使用される場合、用語「安全なステロイド」とは、好酸球および好中球に関連しかつ結果として生じる充血を伴う炎症を処置するが、全身バイオアベイラビリティの欠如を有するかまたは全身吸収後に迅速に不活化される、ステロイドを意味する。
Claims (7)
- 哺乳動物における鼻炎を処置する方法であって、
薬学的に有効な量の組成物を投与する工程
を包含し、
該組成物は、H1アンタゴニスト/抗アレルギー剤と安全なステロイドとを含む、
方法。 - 請求項1に記載の方法であって、前記組成物は、エメダスチン、ロラタジン、5−[2−[4−ビス(4−フルオロフェニル)ヒドロキシメチル−1−ピペリジニル]エチル]−3−メチル]−2−オキサゾリジノンエタンジオエート、デスロラタジン、アゼラスチン、オロパタジン、レボカバスチン、エピナスチン、およびケトチフェンからなる群より選択される、H1アンタゴニスト/抗アレルギー剤を含む、方法。
- 請求項1に記載の方法であって、前記組成物は、リメキソロンおよびロテプレドノールからなる群より選択される、安全なステロイドを含む、方法。
- 請求項2に記載の方法であって、前記組成物は、エメダスチン、オロパタジン、およびデスロラタジンからなる群より選択される、H1アンタゴニスト/抗アレルギー剤を含む、方法。
- 哺乳動物における鼻炎を処置する方法であって、
薬学的に有効な量の組成物を投与する工程
を包含し、
該組成物は、エメダスチンとリメキソロンとを含む、
方法。 - 哺乳動物における鼻炎を処置する方法であって、
薬学的に有効な量の組成物を投与する工程
を包含し、
該組成物は、オロパタジンとリメキソロンとを含む、
方法。 - 哺乳動物における鼻炎を処置する方法であって、
薬学的に有効な量の組成物を投与する工程
を包含し、
該組成物は、デスロラタジンとリメキソロンとを含む、
方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33737101P | 2001-12-05 | 2001-12-05 | |
PCT/US2002/036915 WO2003049770A1 (en) | 2001-12-05 | 2002-11-18 | Use of an h1 antagonist and a safe steroid to treat rhinitis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005511724A true JP2005511724A (ja) | 2005-04-28 |
JP2005511724A5 JP2005511724A5 (ja) | 2006-01-05 |
Family
ID=23320292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003550819A Pending JP2005511724A (ja) | 2001-12-05 | 2002-11-18 | 鼻炎を処置するためのh1アンタゴニストおよび安全なステロイドの使用 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040242638A1 (ja) |
EP (1) | EP1467762B1 (ja) |
JP (1) | JP2005511724A (ja) |
KR (1) | KR20050044550A (ja) |
CN (1) | CN1599625A (ja) |
AT (1) | ATE317268T1 (ja) |
AU (1) | AU2002366567B2 (ja) |
BR (1) | BR0214643A (ja) |
CA (1) | CA2468749A1 (ja) |
CY (1) | CY1105607T1 (ja) |
DE (1) | DE60209154T2 (ja) |
DK (1) | DK1467762T3 (ja) |
ES (1) | ES2258175T3 (ja) |
MX (1) | MXPA04005417A (ja) |
PL (1) | PL369630A1 (ja) |
WO (1) | WO2003049770A1 (ja) |
ZA (1) | ZA200403813B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014501779A (ja) * | 2011-01-04 | 2014-01-23 | イスタ・ファーマシューティカルズ・インコーポレイテッド | ベポタスチン組成物 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
ES2393864T3 (es) | 2002-08-30 | 2012-12-28 | Nycomed Gmbh | El uso de la asociación de ciclesonida y antihistaminas para el tratamiento de rinitis alérgica |
KR20050074577A (ko) * | 2002-11-12 | 2005-07-18 | 알콘, 인코퍼레이티드 | 알레르기성 비염을 치료하기 위한 항알레르기제 및스테로이드의 용도 |
US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
PT2522365T (pt) | 2004-11-24 | 2017-02-08 | Meda Pharmaceuticals Inc | Composições que compreendem azelastina e seus métodos de utilização |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
WO2006097458A1 (en) * | 2005-03-15 | 2006-09-21 | Nycomed Gmbh | Novel combination |
JP5393151B2 (ja) * | 2005-09-01 | 2014-01-22 | メダ アーベー | 抗ヒスタミン剤及びコルチコステロイド含有リポソーム組成物と鼻炎及びその関連疾患を治療するための医薬の製造のためのその使用 |
WO2008098122A2 (en) * | 2007-02-08 | 2008-08-14 | Inspire Pharmaceuticals, Inc. | Method for treating allergic rhinitis without adverse effects |
US20100008868A1 (en) * | 2007-11-27 | 2010-01-14 | Harry Dugger | Sustained remission of atopic dermatitis |
ES2910374T3 (es) | 2009-03-17 | 2022-05-12 | Nicox Ophthalmics Inc | Formulaciones oftálmicas de cetirizina y procedimientos de uso |
US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5879983A (ja) * | 1981-11-06 | 1983-05-13 | Kanebo Ltd | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 |
US5223493A (en) * | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
US4923892A (en) * | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
GB8520662D0 (en) * | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
JPS6310784A (ja) * | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
US5149694A (en) * | 1988-03-09 | 1992-09-22 | Alcon Laboratories, Inc. | Combination of tobramycin and dexamethasone for topical ophthalmic use |
US5192780A (en) * | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
US5668133A (en) * | 1992-12-09 | 1997-09-16 | Alcon Laboratories, Inc. | Ophthalmic compositions comprising emedastine and methods for their use |
JP3527256B2 (ja) * | 1992-12-09 | 2004-05-17 | ロート製薬株式会社 | 抗アレルギー点眼剤 |
US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
US5641805A (en) * | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
WO1997001337A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
BR0015647A (pt) * | 1999-11-18 | 2002-07-16 | Alcon Inc | Uso de um antagonista de h1 e um esteróide seguro para tratar condições dos olhos |
-
2002
- 2002-11-18 WO PCT/US2002/036915 patent/WO2003049770A1/en active IP Right Grant
- 2002-11-18 AU AU2002366567A patent/AU2002366567B2/en not_active Ceased
- 2002-11-18 EP EP02804694A patent/EP1467762B1/en not_active Expired - Lifetime
- 2002-11-18 CA CA002468749A patent/CA2468749A1/en not_active Abandoned
- 2002-11-18 JP JP2003550819A patent/JP2005511724A/ja active Pending
- 2002-11-18 DE DE60209154T patent/DE60209154T2/de not_active Expired - Lifetime
- 2002-11-18 ES ES02804694T patent/ES2258175T3/es not_active Expired - Lifetime
- 2002-11-18 MX MXPA04005417A patent/MXPA04005417A/es active IP Right Grant
- 2002-11-18 DK DK02804694T patent/DK1467762T3/da active
- 2002-11-18 US US10/497,619 patent/US20040242638A1/en not_active Abandoned
- 2002-11-18 AT AT02804694T patent/ATE317268T1/de active
- 2002-11-18 CN CNA028240197A patent/CN1599625A/zh active Pending
- 2002-11-18 PL PL02369630A patent/PL369630A1/xx not_active Application Discontinuation
- 2002-11-18 BR BR0214643-6A patent/BR0214643A/pt not_active IP Right Cessation
- 2002-11-18 KR KR1020047007701A patent/KR20050044550A/ko not_active Application Discontinuation
-
2004
- 2004-05-18 ZA ZA2004/03813A patent/ZA200403813B/en unknown
-
2006
- 2006-05-02 CY CY20061100563T patent/CY1105607T1/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014501779A (ja) * | 2011-01-04 | 2014-01-23 | イスタ・ファーマシューティカルズ・インコーポレイテッド | ベポタスチン組成物 |
US10736841B2 (en) | 2011-01-04 | 2020-08-11 | Bausch & Lomb Incorporated | Bepotastine compositions |
Also Published As
Publication number | Publication date |
---|---|
KR20050044550A (ko) | 2005-05-12 |
AU2002366567B2 (en) | 2006-11-16 |
DE60209154T2 (de) | 2006-08-10 |
BR0214643A (pt) | 2004-11-03 |
WO2003049770A1 (en) | 2003-06-19 |
CA2468749A1 (en) | 2003-06-19 |
ATE317268T1 (de) | 2006-02-15 |
PL369630A1 (en) | 2005-05-02 |
DK1467762T3 (da) | 2006-04-10 |
DE60209154D1 (de) | 2006-04-20 |
ZA200403813B (en) | 2005-07-27 |
EP1467762A1 (en) | 2004-10-20 |
MXPA04005417A (es) | 2004-10-11 |
EP1467762B1 (en) | 2006-02-08 |
CY1105607T1 (el) | 2010-07-28 |
ES2258175T3 (es) | 2006-08-16 |
US20040242638A1 (en) | 2004-12-02 |
CN1599625A (zh) | 2005-03-23 |
AU2002366567A1 (en) | 2003-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006508138A (ja) | アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用 | |
AU772406B2 (en) | Use of H1 antagonist and a safe steroid to treat eye conditions | |
JP2005511724A (ja) | 鼻炎を処置するためのh1アンタゴニストおよび安全なステロイドの使用 | |
JP2001517639A (ja) | 鼻炎/結膜炎および感冒、感冒に似た症状および/または流行性感冒の症状を局所的に治療するための、鎮静作用を有しない抗ヒスタミンおよびα−アドレナリン作動薬を含む組合せ物の使用 | |
CA2387398C (en) | Novel combination of loteprednol and antihistamines | |
RU2361593C3 (ru) | Комбинация азеластина и стероидов | |
US20050222102A1 (en) | Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids | |
JP2014515360A (ja) | フルチカゾンを含む鼻用医薬製剤 | |
US20040097486A1 (en) | Use of an H1 antagonist and a safe steroid to treat eye conditions | |
US20050222205A1 (en) | Treatment of pain with ifendropil | |
US20070043111A1 (en) | Use of ifenprodril in the treatment of pain | |
MXPA06004356A (es) | El uso de ifenprodil en el tratamiento del dolor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051031 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051031 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090710 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090717 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091026 |